z-logo
open-access-imgOpen Access
Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients
Author(s) -
Kurt Van der Speeten,
Kim Govaerts,
O. Anthony Stuart,
Paul H. Sugarbaker
Publication year - 2012
Publication title -
gastroenterology research and practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 45
eISSN - 1687-630X
pISSN - 1687-6121
DOI - 10.1155/2012/378064
Subject(s) - medicine , perioperative , intraperitoneal chemotherapy , malignancy , chemotherapy , cytoreductive surgery , pharmacodynamics , cancer , pharmacokinetics , oncology , surgery , ovarian cancer
Background . The peritoneal surface is an acknowledged locoregional failure site of abdominal malignancies. Previous treatment attempts with medical therapy alone did not result in long-term survival. During the last two decades, new treatment protocols combining cytoreductive surgery with perioperative intraperitoneal and intravenous cancer chemotherapy have demonstrated very encouraging clinical results. This paper aims to clarify the pharmacologic base underlying these treatment regimens. Materials and Methods . A review of the current pharmacologic data regarding these perioperative chemotherapy protocols was undertaken. Conclusions . There is a clear pharmacokinetic and pharmacodynamic rationale for perioperative intraperitoneal and intravenous cancer chemotherapy in peritoneal surface malignancy patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom